An Open-Label, Randomized, Multicenter Phase III Study in Patients With HER2-Positive Metastatic Breast Cancer Responding to First Line Treatment With Intravenous Trastuzumab for at Least 3 Years and Investigating Patient Preference for Subcutaneous Trastuzumab

Trial Profile

An Open-Label, Randomized, Multicenter Phase III Study in Patients With HER2-Positive Metastatic Breast Cancer Responding to First Line Treatment With Intravenous Trastuzumab for at Least 3 Years and Investigating Patient Preference for Subcutaneous Trastuzumab

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Trastuzumab (Primary) ; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms Metaspher
  • Sponsors Roche
  • Most Recent Events

    • 01 Sep 2017 Primary endpoint (Percentage of Participants With Preference for Either SC or IV Route of Administration According to Participant Preference Questionnaire (PPQ) Score) has been met, according to the results published in the European Journal of Cancer
    • 01 Sep 2017 Results published in the European Journal of Cancer
    • 23 Aug 2017 Planned End Date changed from 1 Aug 2019 to 10 Aug 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top